Relmada Therapeutics, Inc. (RLMD)
| Market Cap | 581.82M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -143.28M |
| Shares Out | 29.99M |
| EPS (ttm) | -6.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,066 |
| Open | 18.77 |
| Previous Close | 18.64 |
| Day's Range | 18.01 - 19.40 |
| 52-Week Range | 16.23 - 36.93 |
| Beta | 0.52 |
| Analysts | Buy |
| Price Target | 61.64 (+217.7%) |
| Earnings Date | May 5, 2022 |
About RLMD
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for RLMD stock is "Buy." The 12-month stock price forecast is 61.64, which is an increase of 217.73% from the latest price.
News
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
CORAL GABLES, Fla. , May 5, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a c...
Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology
CORAL GABLES, Fla. , April 29, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today...
Relmada Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
CORAL GABLES, Fla. , April 28, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced...
Relmada Therapeutics to Present Data at the Ketamine & Related Compounds International Hybrid Conference 2022
CORAL GABLES, Fla. , April 4, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today ...
Here's Why Relmada Therapeutics Shares Are Rising
Relmada Therapeutics Inc (NASDAQ: RLMD) shares are trading higher by 7.2% at $25.01 after the company reported better-than-expected fourth-quarter EPS results. Relmada Therapeutics reported quarterly lo...
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
CORAL GABLES, Fla., March 23, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a...
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webca...
CORAL GABLES, Fla., March 16, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced ...
Relmada Therapeutics to Participate in Fireside Chats at Two Upcoming Healthcare Events
CORAL GABLES, Fla., March 10, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced ...
Relmada Aces REL-1017 Vs Ketamine Study For Abuse Potential
Relmada Therapeutics Inc (NASDAQ: RLMD) has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive disorder or MDD. REL-1017 is a novel NMDA receptor (NMDA...
Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential
CORAL GABLES, Fla., Feb. 23, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced t...
Relmada Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
CORAL GABLES, Fla., Feb. 10, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced t...
Wall Street Analysts See a 231% Upside in Relmada Therapeutics, Inc. (RLMD): Can the Stock Really Move This High?
The mean of analysts' price targets for Relmada Therapeutics, Inc. (RLMD) points to a 231.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem...
Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry
CORAL GABLES, Fla., Dec. 22, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced t...
Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
CORAL GABLES, Fla., Dec. 14, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced t...
Relmada Stock Falls After Equity Raise Of $150M To Fund Depression Candidate
Relmada Therapeutics Inc (NASDAQ: RLMD) priced an upsized underwritten public offering of 8.82 million shares at $17.00 per share, with gross proceeds of approximately $150 million. The offer price rep...
Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
CORAL GABLES, Fla., Dec. 8, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced th...
Relmada Therapeutics Announces Proposed Public Offering of Common Stock
CORAL GABLES, Fla., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announc...
Relmada Therapeutics to Present Data at the 60th Annual Meeting of the American College of Neuropsychopharmacology
CORAL GABLES, Fla., Dec. 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today th...
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
CORAL GABLES, Fla., Nov. 11, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a ...
Relmada Therapeutics to Present at the Jefferies London Healthcare Conference
CORAL GABLES, Fla., Nov. 9, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced th...
Relmada Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November ...
CORAL GABLES, Fla., Nov. 4, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced th...
Relmada Therapeutics to Present Data at the Neuroscience Education Institute Congress
CORAL GABLES, Fla., Oct. 29, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced t...
Relmada Therapeutics Provides Regulatory and Development Updates on Ongoing Late-Stage Clinical Program for REL-1017 ...
CORAL GABLES, Fla., Oct. 4, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided reg...
Relmada Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
CORAL GABLES, Fla., Sept. 17, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced ...
Relmada Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
CORAL GABLES, Fla., Sept. 3, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced t...